These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results. Kuhl H, Stevenson J. Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155 [Abstract] [Full Text] [Related]
4. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Banks E, Canfell K. Am J Epidemiol; 2009 Jul 01; 170(1):24-8. PubMed ID: 19468078 [Abstract] [Full Text] [Related]
5. Postmenopausal hormones and coronary artery disease: potential benefits and risks. Lobo RA. Climacteric; 2007 Oct 01; 10 Suppl 2():21-6. PubMed ID: 17882668 [Abstract] [Full Text] [Related]
8. Implications of recent clinical trials of postmenopausal hormone therapy for management of cardiovascular disease. Rossouw JE. Ann N Y Acad Sci; 2006 Nov 01; 1089():444-53. PubMed ID: 17261787 [Abstract] [Full Text] [Related]
11. Postmenopausal hormone therapy before and after the women's health initiative study: what consequences? Mikkola TS, Clarkson TB, Notelovitz M. Ann Med; 2004 Nov 01; 36(6):402-13. PubMed ID: 15513292 [Abstract] [Full Text] [Related]
12. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Skouby SO, Al-Azzawi F, Barlow D, Calaf-Alsina Erdogan Ertüngealp J, Gompel A, Graziottin A, Hudita D, Pines A, Rozenberg S, Samsioe G, Stevenson JC, European Menopause and Andropause Society. Maturitas; 2005 May 16; 51(1):8-14. PubMed ID: 15883103 [Abstract] [Full Text] [Related]
13. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI. Clanget C, Hinke V, Lange S, Fricke R, Botko R, Pfeilschifter J. Exp Clin Endocrinol Diabetes; 2005 Oct 16; 113(9):529-33. PubMed ID: 16235155 [Abstract] [Full Text] [Related]
14. Primary prevention of coronary heart disease in women. Rees M, Stevenson J, British Menopause Society Council. Menopause Int; 2008 Mar 16; 14(1):40-5. PubMed ID: 18380961 [Abstract] [Full Text] [Related]
15. A comparative review of the risks and benefits of hormone replacement therapy regimens. Warren MP. Am J Obstet Gynecol; 2004 Apr 16; 190(4):1141-67. PubMed ID: 15118656 [Abstract] [Full Text] [Related]
16. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? Rosano GM, Vitale C, Fini M. Ann N Y Acad Sci; 2006 Dec 16; 1092():341-8. PubMed ID: 17308159 [Abstract] [Full Text] [Related]
17. Pitfalls of the WHIs: Women's Health Initiative. Mastorakos G, Sakkas EG, Xydakis AM, Creatsas G. Ann N Y Acad Sci; 2006 Dec 16; 1092():331-40. PubMed ID: 17308158 [Abstract] [Full Text] [Related]
18. Hormones, menopause, and heart disease: making sense of the Women's Health Initiative. Derry PS. Womens Health Issues; 2004 Dec 16; 14(6):212-9. PubMed ID: 15589771 [Abstract] [Full Text] [Related]
19. Postmenopausal hormone therapy: have HERS2 and WHI given us any new information? Fylstra DL. J S C Med Assoc; 2002 Dec 16; 98(8):299-304. PubMed ID: 12532655 [Abstract] [Full Text] [Related]
20. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Guay MP, Dragomir A, Pilon D, Moride Y, Perreault S. Pharmacoepidemiol Drug Saf; 2007 Jan 16; 16(1):17-27. PubMed ID: 16794994 [Abstract] [Full Text] [Related] Page: [Next] [New Search]